Public Private Partnerships / European Investment Bank / Sustainable Small / Young Innovative Company / Medium Sized Biotech Enterprises / EuropaBio / LETTER FROM EUROPABIO / /
Continent
Africa / Europe / /
Event
Environmental Issue / /
Facility
Plant Biotechnology / /
IndustryTerm
treatment of cancers / biotechnology / energy security / patient-centred healthcare systems / healthcare biotech / financial asset management / biotechnology innovation / human and animal healthcare / energy generation / healthcare policies / environmental products / healthcare / sustainable energy / healthcare systems / food / energy / food needs / crude oil / biotechnology industry / food security / healthcare products / food security crisis / pharmaceutical regulatory competences / manufacturing / food supplies / healthcare needs / tried and tested solutions / biotechnology development organisations / biotechnology can / healthcare affordability / chemicals / sustainable agricultural and industrial products / unnecessary healthcare interventions / /
MedicalCondition
rare diseases / given disease / epidemics / very rare diseases / cancers / inflammatory and infectious diseases / disease / diseases / /
MedicalTreatment
cell therapy / /
OperatingSystem
Spring / /
Organization
on 2020EuropaBio’s mission / European Association for BioIndustries / EuropaBio-EBE Task Force on Rare Diseases / European Parliament / Task Force / EMEA / EuropaBio’s mission / European Commission / European Union / /
Person
ANDREA RAPPAGLIOSI / NATHALIE MOLL / /
Position
VP / SECRETARY GENERAL / general scientific aspects / CHAIRMAN / ’S SECRETARY GENERAL / ’S CHAIRMAN / /
Product
SMEs / /
Technology
cell therapy / antibodies / biotechnology / drug discovery / biofuels / nine European Technology / drug development / /
TM Annual Report June[removed]June 2010 FOREWORD ABOUT